Overview

Ruxolitinib With Calcineurin and Methotrexate vs. Calcineurin Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation

Status:
Recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

Low Dose Ruxolitinib with Calcineurin and Methotrexate vs. Calcineurin plus Methotrexate and Mycophenolate mofetil as Graft Versus Host Disease prophylaxis for HLA-haploidentical hematopoietic stem cell transplantation in low-dose antithymocyte globulin (ATG) system.

Phase:

Phase 4

Details

Lead Sponsor:

Zhejiang University

Treatments:

Methotrexate
Mycophenolic Acid